The development of in vitro carcinogenesis model, and the elucidation of mechanism of gastric and intestinal phenotypes aiming at the clinical application
| Project/Area Number |
17K09355
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
MIZOSHITA Tsutomu 名古屋市立大学, 医薬学総合研究院(医学), 研究員 (40347414)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
片野 敬仁 名古屋市立大学, 医薬学総合研究院(医学), 助教 (50768372)
城 卓志 名古屋市立大学, 医薬学総合研究院(医学), 名誉教授 (30231369)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | in vitro 三次元培養系 / 炎症性腸疾患 / 潰瘍性大腸炎 / クローン病 / 腸管ベーチェット病 / 長期in vitro 三次元培養系 / 胃幹細胞 / in vitro 三次元培養腺管 / 幹細胞 / in vitro三次元培養系 / 胃型形質 / 腸型形質 |
|---|
| Outline of Final Research Achievements |
The establishment of the in vitro carcinogenesis model enables the dynamic, chronological, and real-time analyses of the alimentary canal mucosa duct and is thought to be particularly important to the elucidation of the mechanism of "the cancerogenesis from chronic inflammation". It is important to perform the immunosuppressive treatment including anti-TNF-α antibodies for the refractory inflammatory bowel diseases (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) in consideration of the history of treatment of the case and clinical course.
|
| Academic Significance and Societal Importance of the Research Achievements |
in vitro発癌モデルの確立により、in vivoの実験に用いる実験動物の数を最小限に留めることが可能となり、動物愛護の観点から社会的にも大変意義深い。また、抗TNF-α抗体製剤を含めた免疫抑制治療は高額になることが多く、これらの治療を適切に行うことが医療経済学上も重要である。
|
Report
(5 results)
Research Products
(24 results)
-
[Journal Article] Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice,2020
Author(s)
Marutani, Y., Mizoshita, T., Sugiyama, T., Togawa, S., Katano, T., Yamada, T., Hirata, Y., Kimura, Y., Miyaki, T., Inoue, Y., Suzuki, E., Sasaki, M., and Kataoka, H.
-
Journal Title
Indian J Gastroenterol.
Volume: 39
Issue: 6
Pages: 565-575
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment.2019
Author(s)
Suzuki T, Mizoshita T, Sugiyama T, Hirata Y, Kimura Y, Suzuki Y, Yamada T, Tsukamoto H, Mizushima T, Sugimura N, Katano T, Tanida S, Kataoka H, Sasaki M.
-
Journal Title
Case Rep Gastroenterol.
Volume: 13
Issue: 1
Pages: 37-49
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy2017
Author(s)
Mizoshita, T., Katano, T., Tanida, S., Hirano, A., Miyaki, T., Ozeki, K., Suzuki, Y., Sugimura, N., Kataoka, H. & Joh, T.
-
Journal Title
Medicine (Baltimore)
Volume: 96
Issue: 32
Pages: e7800-e7800
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy.2017
Author(s)
Mizoshita T, Ando M, Sagawa H, Mori Y, Katano T, Ozeki K, Tanida S, Okamoto Y, Shimura T, Kubota E, Kataoka H, Kamiya T, Joh T.
-
Journal Title
Clin J Gastroenterol.
Volume: in press
Issue: 3
Pages: 250-254
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
